Lupus
10 videos · updated daily
26:50 Eric Morand on the Enpatoran Phase 2 Lupus Trial
Professor Eric Morand, Head of Rheumatology at Monash Health, discusses with the Lupus Forum his paper on cohort B of a multicentre, double-blind, placebo-controlled Phase 2 dose-finding trial of enpatoran, a TLR7/8 inhibitor, in moderate-to-severe lupus.
1:21 Obinutuzumab in Active Lupus: The ALLEGORY Trial
Dr. Glaucomflecken summarizes for NEJM Group the ALLEGORY trial of obinutuzumab added to standard therapy in adults with active systemic lupus erythematosus.
4:39 Daxdilimab in Discoid Lupus: Phase 2 Results
Speaking at the EADV Congress, Victoria Werth, MD, of the University of Pennsylvania tells Dermatology Times about Phase 2 results for daxdilimab, an investigational anti-ILT7 antibody, in discoid lupus, across two doses over 24 weeks.
18:12 Lupus and Clinical Trial Participation
Dr. Ben Hsu, a rheumatologist and medical scientist at Adicet Bio, explains to the Lupus Research Alliance community why clinical trial participation matters for people living with lupus.
15:45 CISCRP Discusses Clinical Trials Focusing on the Patient's Point of View
Clinical Trials vendor Curebase discusses modernization in clinical trials and then interviews a Lupus clinical trials participant who discusses her experiences about the trial including informed consent and travel.
1:04:51 Lupus Clinical Trials: Advocacy Through Participation
Dr. Fotios Koumpouras, Director of the Yale Lupus Program, and Arnita Roberts-Christie of the Lupus Foundation discuss why clinical trials matter, how participation advances lupus research, and research updates on lupus nephritis.
13:24 REGENCY: Obinutuzumab in Lupus Nephritis
Richard Furie, MD, lead investigator of the Phase 3 REGENCY trial published in the New England Journal of Medicine, discusses results of obinutuzumab with standard therapy in lupus nephritis and the history of the drug with Nephrology Times.
37:54 Taking Part in a Lupus Clinical Study
Andreas Reiff, MD, SVP and global head of immunology and inflammation at Parexel, explains what people with lupus need to know about taking part in clinical studies, for Lupus LA.
50:54 REGENCY: Obinutuzumab in Lupus Nephritis
Brad Rovin, MD, of Ohio State University Wexner Medical Center and Ana Malvar, MD, of Hospital Fernandez in Buenos Aires present the background and central results of the phase 3 REGENCY study of obinutuzumab in active lupus nephritis, for MARKUS at HOMe.
31:30 How Lupus Clinical Trials Work
A Lupus Research Alliance panel with Dr. Maria Dall'Era of UCSF, Albert T. Roy and Ebony Scott of Lupus Therapeutics and Dr. Shalabh Singhal of Bristol-Myers Squibb explains how lupus clinical trials work and why diverse participation matters.